V
Vivoryon Therapeutics
Biopharmaceutical company focused on the development of innovative small molecule drugs
About Vivoryon Therapeutics
Vivoryon Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule-based medicines for the treatment of Alzheimer's disease and other neurodegenerative disorders. The company's therapeutic approach is centered on the inhibition of the enzyme glutaminyl cyclase (QC), which is involved in the formation of neurotoxic pyroglutamate-Abeta (pGlu-Abeta) oligomers. These oligomers are believed to be a key driver of Alzheimer's disease pathogenesis.
Read full description
Vivoryon's lead product candidate, Varoglutamstat (PQ912), is an orally available QC inhibitor that has completed a Phase 2b clinical trial in patients with early Alzheimer's disease. The company is also developing a pipeline of other QC inhibitors for the treatment of other neurodegenerative disorders, as well as for other indications such as cancer and fibrosis.
Vivoryon's business model is focused on the development and commercialization of its product candidates. The company plans to partner with larger pharmaceutical companies to commercialize its products in major markets, while retaining commercialization rights in certain niche markets. Vivoryon's primary source of revenue is expected to be from milestone payments, royalties, and product sales.
At a glance
- Founded
- 1997
- Headquarters
- Halle (Saale), Germany
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Vivoryon Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Ingenium Pharamceutical
CFH Management GmbH
Bmp Ventures
IBG Investment Company Saxony-Anhalt
TVM Capital Life Science
EQT Life Sciences- BVBB Biotech Ventures
Andera Partners
Series B and later2 investors entered at this stage
Biogen
Yorkville Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vivoryon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vivoryon Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.